U.S. markets open in 5 hours 47 minutes
  • S&P Futures

    3,852.25
    +7.25 (+0.19%)
     
  • Dow Futures

    31,120.00
    +24.00 (+0.08%)
     
  • Nasdaq Futures

    13,349.75
    +55.50 (+0.42%)
     
  • Russell 2000 Futures

    2,158.40
    +0.70 (+0.03%)
     
  • Crude Oil

    52.97
    -0.34 (-0.64%)
     
  • Gold

    1,869.10
    +2.60 (+0.14%)
     
  • Silver

    25.92
    +0.15 (+0.58%)
     
  • EUR/USD

    1.2123
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    1.0900
    0.0000 (0.00%)
     
  • Vix

    21.37
    -1.87 (-8.05%)
     
  • GBP/USD

    1.3717
    +0.0062 (+0.45%)
     
  • USD/JPY

    103.4910
    -0.0790 (-0.08%)
     
  • BTC-USD

    33,803.84
    -1,147.84 (-3.28%)
     
  • CMC Crypto 200

    669.45
    -31.16 (-4.45%)
     
  • FTSE 100

    6,767.37
    +26.98 (+0.40%)
     
  • Nikkei 225

    28,756.86
    +233.60 (+0.82%)
     

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Biogen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 12, 2021 - BIIB

Newsfile Corp.
·2 min read

New York, New York--(Newsfile Corp. - December 22, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Biogen Inc. ("Biogen") (NASDAQ: BIIB) between October 22, 2019 and November 6, 2019. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Central District of California. To get more information go to:

https://www.zlk.com/pslra-1/biogen-inc-loss-submission-form?prid=11755&wire=5

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab's effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding the effectiveness of aducanumab, Biogen's investigational human monoclonal antibody studied for the treatment of early Alzheimer's disease; (3) the PRIME study did not and would not provide necessary data regarding aducanumab's effectiveness; (4) the data provided by the Company to the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

If you suffered a loss in Biogen you have until January 12, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/70861